Baxter International Inc. (BAX) EPS CAGR:43.24%(TTM)
The eps cagr for Baxter International Inc. (BAX) is +43.24% over the latest trailing 12-month period. EPS CAGR uses precomputed diluted earnings history where available.
The EPS CAGR for Baxter International Inc. (BAX) stock is 43.24% over the past 12 months. The 3 year CAGR is 34.27% and the 5 year CAGR is 11.55%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how Baxter International Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
BAX EPS CAGR Chart
Baxter International Inc. (BAX)
BAX Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 20 quarters.
BAX EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $-1.27 | $-1.75 | $-0.48 | +0.00% | N/A |
| 2024 | $5.25 | $-1.27 | $-6.52 | -124.19% | N/A |
| 2023 | $-4.83 | $5.25 | +$10.08 | +0.00% | N/A |
| 2022 | $2.56 | $-4.83 | $-7.39 | -288.67% | N/A |
| 2021 | $2.17 | $2.56 | +$0.39 | +17.97% | +17.97% |
| 2020 | $1.97 | $2.17 | +$0.20 | +10.15% | +10.15% |
| 2019 | $3.04 | $1.97 | $-1.07 | -35.20% | -35.20% |
| 2018 | $1.11 | $3.04 | +$1.93 | +173.87% | +173.87% |
| 2017 | $9.09 | $1.11 | $-7.98 | -87.79% | -87.79% |
| 2016 | $1.78 | $9.09 | +$7.31 | +410.67% | +410.67% |
| 2015 | $4.61 | $1.78 | $-2.83 | -61.39% | -61.39% |
| 2014 | $3.70 | $4.61 | +$0.91 | +24.59% | +24.59% |
| 2013 | $4.22 | $3.70 | $-0.52 | -12.32% | -12.32% |
| 2012 | $3.91 | $4.22 | +$0.31 | +7.93% | +7.93% |
| 2011 | $2.41 | $3.91 | +$1.50 | +62.24% | +62.24% |
| 2010 | $3.63 | $2.41 | $-1.22 | -33.61% | -33.61% |
| 2009 | $3.22 | $3.63 | +$0.41 | +12.73% | +12.73% |
| 2008 | $2.65 | $3.22 | +$0.57 | +21.51% | +21.51% |
| 2007 | $2.15 | $2.65 | +$0.50 | +23.26% | +23.26% |
| 2006 | $1.54 | $2.15 | +$0.61 | +39.61% | +39.61% |
| 2005 | $0.63 | $1.54 | +$0.91 | +144.44% | +144.44% |
| 2004 | $1.51 | $0.63 | $-0.88 | -58.28% | -58.28% |
| 2003 | $1.71 | $1.51 | $-0.20 | -11.70% | -11.70% |
| 2002 | $1.13 | $1.71 | +$0.58 | +51.33% | +51.33% |
| 2001 | $1.27 | $1.13 | $-0.14 | -11.02% | -11.02% |
| 2000 | $1.38 | $1.27 | $-0.11 | -7.97% | -7.97% |
| 1999 | $0.56 | $1.38 | +$0.82 | +146.43% | +146.43% |
| 1998 | $0.54 | $0.56 | +$0.02 | +3.70% | +3.70% |
| 1997 | $1.23 | $0.54 | $-0.69 | -56.10% | -56.10% |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $-0.03 | +98.6% | -112.0% |
| Q4 2025 | $-2.16 | -2313.4% | -116.0% |
| Q3 2025 | $-0.09 | -149.7% | -132.0% |
| Q2 2025 | $0.18 | -28.0% | +129.5% |
| Q1 2025 | $0.25 | +125.0% | +243.4% |
| Q4 2024 | $-1.00 | -457.1% | -308.3% |
| Q3 2024 | $0.28 | +145.9% | -94.3% |
| Q2 2024 | $-0.61 | -937.9% | -117.9% |
| Q1 2024 | $0.07 | -84.8% | -19.1% |
| Q4 2023 | $0.48 | -90.3% | +33.3% |
| Q3 2023 | $4.95 | +1867.9% | +184.9% |
| Q2 2023 | $-0.28 | -411.1% | -156.0% |
| Q1 2023 | $0.09 | -75.0% | -35.7% |
| Q4 2022 | $0.36 | +106.2% | -25.0% |
| Q3 2022 | $-5.83 | -1266.0% | -747.8% |
| Q2 2022 | $0.50 | +257.1% | -15.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider